What is claimed is:

1. A compound represented by the formula (I)



(I)

wherein:

X is selected from the group consisting of,

(i) a five membered substituted or unsubstituted heterocyclic radical containing from 1 to 4 hetero atoms independently selected from sulfur, nitrogen or oxygen; and

(ii) a fused bicyclic radical wherein a carbocyclic group is fused to two adjacent carbon atoms of the five membered heterocyclic radical, (i);

Y_1 is a bond or divalent linking group containing 1 to 9 atoms;

Y_2 and Y_3 are divalent linking groups independently selected from $-CH_2-$, $-O-$, or $-S-$;

Z is an Acidic Group;

R1 is C_1-C_{10} alkyl, aryl, C_3-C_8 cycloalkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_6-C_{20} aralkyl, C_6-C_{20} alkaryl, C_1-C_{10} haloalkyl, C_6-C_{20} aryloxy, or C_1-C_{10} alkoxy;

R2 is hydrogen, halogen, C_1-C_{10} haloalkyl, C_1-C_{10} alkoxy, C_1-C_{10} alkyl, C_3-C_8 cycloalkyl, Acidic Group, or $-(CH_2)_{1-7}$-(Acidic Group);

R3 is hydrogen, halogen, C_1-C_{10} alkyl, aryl, C_1-C_{10} haloalkyl, C_1-C_{10} alkoxy, C_6-C_{20} aryloxy, or C_3-C_8 cycloalkyl;

R4 is C_1-C_4 alkyl, C_3-C_4 cycloalkyl, $-(CH_2)_{1-7}$-(C_3-C_4 cycloalkyl), C_2-C_4 alkenyl, C_2-C_4 alkynyl, benzyl, or aryl; and

n is 0, 1, 2, 3, 4, 5, or 6;

or a pharmaceutically acceptable salt, solvate, or prodrug derivative thereof.

2. The compound of claim 1 wherein X is a heterocyclic radical selected from the group consisting of substituents represented by the following formulae:







, and



;

where R10 is a radical selected from hydrogen or C_1-C_4 alkyl; and R11 is a radical selected from hydrogen, halo, C_1-C_{10} alkyl, C_1-C_{10} haloalkyl, C_1-C_{10} alkoxy, aryl, or C_6-C_{20} aryloxy.

3. The compound of claim 2 wherein the heterocyclic radical is selected from the group consisting of substituents represented by the formulae;



,



,



, and



4. The compound of claim 1 or 2 or 3 wherein Y_1 is a divalent linking group selected from the following formulae:



where R13 is hydrogen, methyl, or ethyl.

5. The compound of claim 4 wherein Y_1 is the divalent linking group;



6. The compound of claim 1 or 2 or 3 wherein the acidic group Z is selected from the following:



tetrazolyl,

$-SO_3H$,







or



;

where R12 is C_1-C_{10} alkyl, aryl, C_6-C_{20} alkaryl, or C_6-C_{20} aralkyl.

7. The compound of claim 6 wherein the acidic group Z is selected from -5-tetrazolyl, N-acyl sulfonamide, $-SO_3H$, or carboxyl.

8. The compound of claim 7 wherein the acidic group Z is carboxyl.

9. The compound of claim 1 or 2 or 3 wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, or 2-propenyl.

10. The compound of claim 1 or 2 or 3 wherein R2 and R3 are independently selected from hydrogen or methyl, ethyl, methoxy, ethoxy, halo, or $-CF_3$.

11. The compound of claim 10 wherein R2 and R3 are hydrogen.

12. The compound of claim 1 or 2 or 3 wherein R4 is ethyl, propyl, or isopropyl.

13. The compound of claim 1 or 2 or 3 wherein the numerical value of subscript n is 1.

14. The compound of claim 1 or 2 or 3 wherein Y_2 and Y_3 are both -O-.

15. The compound of claim 1 or 2 or 3 in the form of a sodium salt.

16. The compound of claim 1 or 2 or 3 in the form of a prodrug which is an ester of the Acidic Group; provided that the Acidic Group is a carboxyl.

17. The compound of claim 16 wherein the Acidic Group is carboxyl and the prodrug is selected from methyl ester, ethyl ester, propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester, or N,N-diethylglycolamido ester.

18. The compound of claim 1 wherein the R1, R2, R3 and R4 groups for substitution in formula (I) are selected from the following variables coded R01 thru R16

R variables Combination Code	R1 group choice	R2 group choice	R3 group choice	R4 group choice
R01	R1	R2	R3	R4
R02	R1	R2	R3	PG1-R4
R03	R1	R2	PG1-R3	R4
R04	R1	R2	PG1-R3	PG1-R4
R05	R1	PG1-R2	R3	R4
R06	R1	PG1-R2	R3	PG1-R4
R07	R1	PG1-R2	PG1-R3	R4
R08	R1	PG1-R2	PG1-R3	PG1-R4
R09	PG1-R1	R2	R3	R4
R10	PG1-01	R2	R3	PG1-R4
R11	PG1-R1	R2	PG1-R3	R4
R12	PG1-R1	R2	PG1-R3	PG1-R4
R13	PG1-R1	PG1-R2	R3	R4
R14	PG1-R1	PG1-R2	R3	PG1-R4
R15	PG1-R1	PG1-R2	PG1-R3	R4
R16	PG1-R1	PG1-R2	PG1-R3	PG1-R4

and;

the Y1, Y2, and Y3 groups for substitution in formula (I) are selected from the following variables coded Y01 thru Y27:

Y variables combination code	Y1 group choice	Y2 group choice	Y3 group choice
Y01	Y1	Y2	Y3
Y02	Y1	Y2	PG1-Y3
Y03	Y1	Y2	PG2-Y3
Y04	Y1	PG1-Y2	Y3
Y05	Y1	PG2-Y2	Y3
Y06	Y1	PG1-Y2	PG1-Y3
Y07	Y1	PG1-Y2	PG2-Y3
Y08	Y1	PG2-Y2	PG1-Y3
Y09	Y1	PG2-Y2	PG2-Y3
Y10	PG1-Y1	Y2	Y3
Y11	PG1-Y1	Y2	PG1-Y3
Y12	PG1-Y1	Y2	PG2-Y3
Y13	PG1-Y1	PG1-Y2	Y3
Y14	PG1-Y1	PG1-Y2	PG1-Y3
Y15	PG1-Y1	PG1-Y2	PG2-Y3
Y16	PG1-Y1	PG2-Y2	Y3
Y17	PG1-Y1	PG2-Y2	PG1-Y3
Y18	PG1-Y1	PG2-Y2	PG2-Y3
Y19	PG2-Y1	Y2	Y3
Y20	PG2-Y1	Y2	PG1-Y3
Y21	PG2-Y1	Y2	PG2-Y3
Y22	PG2-Y1	PG1-Y2	Y3
Y23	PG2-Y1	PG1-Y2	PG1-Y3
Y24	PG2-Y1	PG1-Y2	PG2-Y3
Y25	PG2-Y1	PG2-Y2	Y3
Y26	PG2-Y1	PG2-Y2	PG1-Y3
Y27	PG2-Y1	PG2-Y2	PG2-Y3

and;

the X and Z groups and the n variable for substitution in formula (I) are selected from the following variables coded XZn01 thru XZn24:

5

XZn variables combination code	X group choice	Z Group Choice	n integer group choice
XZn01	X	Z	n
XZn02	X	Z	PG1-n
XZn03	X	Z	PG2-n
XZn04	X	PG1-Z	n
XZn05	X	PG2-Z	n
XZn06	X	PG3-Z	n
XZn07	X	PG1-Z	PG1-n
XZn08	X	PG2-Z	PG1-n
XZn09	X	PG3-Z	PG1-n
XZn10	X	PG1-Z	PG2-n
XZn11	X	PG2-Z	PG2-n
XZn12	X	PG3-Z	PG2-n
XZn13	PG1-X	Z	n
XZn14	PG1-X	Z	PG1-n
XZn15	PG1-X	Z	PG2-n
XZn16	PG1-X	PG1-Z	n
XZn17	PG1-X	PG2-Z	n
XZn18	PG1-X	PG3-Z	n
XZn19	PG2-X	PG1-Z	PG1-n
XZn20	PG2-X	PG2-Z	PG1-n
XZn21	PG2-X	PG3-Z	PG1-n
XZn22	PG2-X	PG1-Z	PG2-n
XZn23	PG2-X	PG2-Z	PG2-n
XZn24	PG2-X	PG3-Z	PG2-n

5

19. A compound effective as a leukotriene B4 antagonist, described by formula (II):



(II)

wherein;

X2 is a heterocyclic radical selected from,



,



,



, or



;

R21 is ethyl, 2-propen-1-yl, 3-propen-1-yl, n-propyl, iso-propyl, n-butyl, sec-butyl, or tert-butyl; and

R22 is hydrogen, n-butyl, sec-butyl, flouro, chloro, $-CF_3$, or tert-butyl.

Z2 is the Acidic Group selected from carboxyl, tetrazolyl, or N-sulfonamidyl;

or a salt, solvate or prodrug thereof.

20. A compound selected from the following:



























,



,



,



,



,











, or



;

or an acid, salt, solvate or prodrug derivative thereof.

21. A compound selected from the following:



,



,



,



,



, or



;

or an acid, salt, solvate or prodrug derivative thereof.

22. A compound of claim 20 or 21 wherein the acid, salt and prodrug derivatives are respectively selected from; carboxylic acid, sodium salt, and ester prodrug.

23. A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or 20 or 21 and a pharmaceutically acceptable carrier or diluent.

24. A method for the treatment or prevention of Inflammatory Diseases, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or 20 or 21.

25. A method for in vivo inhibition of leukotriene B_4 in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound according to claim 1 or 2 or 3 or 18 or 19 or 20 or 21.

26. The method of claim 25 wherein the route of administration is oral and the dose is about 1 to about 1000 milligrams per day.

27. The method of claim 25 wherein the route of administration is parenteral and the dose is about 0.1 to about 100 milligrams per day.

28. A compound of claim 1 or 2 or 3 or 18 or 19 or 20 or 21 for use as a medicament in the treatment or prevention of Inflammatory Diseases.

29. A compound of claim 1 or 2 or 3 or 18 or 19 or 20 or 21 for use as a medicament in the in vivo inhibition of leukotriene B_4 in a mammal in need thereof.

30. A compound of Formula (I) substantially as hereinbefore described which reference to any one of the Examples or Reaction Schemes.

31. A process for preparing a compound of Formula (I) substantially as hereinbefore described with reference to any one of the Examples or Reaction Schemes.